vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and LiveRamp Holdings, Inc. (RAMP). Click either name above to swap in a different company.
LiveRamp Holdings, Inc. is the larger business by last-quarter revenue ($212.2M vs $139.2M, roughly 1.5× ADMA BIOLOGICS, INC.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs 18.8%, a 16.7% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs 8.6%). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 11.1%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
LiveRamp Holdings, Inc., is an American SaaS company that offers a data connectivity platform whose services include data onboarding, the transfer of offline data online for marketing purposes.
ADMA vs RAMP — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $212.2M |
| Net Profit | $49.4M | $39.9M |
| Gross Margin | 63.8% | 71.9% |
| Operating Margin | 45.1% | 18.6% |
| Net Margin | 35.5% | 18.8% |
| Revenue YoY | 18.4% | 8.6% |
| Net Profit YoY | -55.9% | 255.7% |
| EPS (diluted) | $0.20 | $0.62 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $212.2M | ||
| Q3 25 | $134.2M | $199.8M | ||
| Q2 25 | $122.0M | $194.8M | ||
| Q1 25 | $114.8M | $188.7M | ||
| Q4 24 | $117.5M | $195.4M | ||
| Q3 24 | $119.8M | $185.5M | ||
| Q2 24 | $107.2M | $176.0M | ||
| Q1 24 | $81.9M | $171.9M |
| Q4 25 | $49.4M | $39.9M | ||
| Q3 25 | $36.4M | $27.4M | ||
| Q2 25 | $34.2M | $7.7M | ||
| Q1 25 | $26.9M | $-6.3M | ||
| Q4 24 | $111.9M | $11.2M | ||
| Q3 24 | $35.9M | $1.7M | ||
| Q2 24 | $32.1M | $-7.5M | ||
| Q1 24 | $17.8M | $-5.4M |
| Q4 25 | 63.8% | 71.9% | ||
| Q3 25 | 56.3% | 70.2% | ||
| Q2 25 | 55.1% | 70.1% | ||
| Q1 25 | 53.2% | 69.3% | ||
| Q4 24 | 53.9% | 71.9% | ||
| Q3 24 | 49.8% | 72.4% | ||
| Q2 24 | 53.6% | 70.6% | ||
| Q1 24 | 47.8% | 72.2% |
| Q4 25 | 45.1% | 18.6% | ||
| Q3 25 | 38.0% | 10.7% | ||
| Q2 25 | 35.1% | 3.7% | ||
| Q1 25 | 30.4% | -6.1% | ||
| Q4 24 | 32.6% | 7.5% | ||
| Q3 24 | 33.1% | 4.0% | ||
| Q2 24 | 36.6% | -3.0% | ||
| Q1 24 | 26.7% | -8.3% |
| Q4 25 | 35.5% | 18.8% | ||
| Q3 25 | 27.1% | 13.7% | ||
| Q2 25 | 28.1% | 4.0% | ||
| Q1 25 | 23.4% | -3.3% | ||
| Q4 24 | 95.2% | 5.7% | ||
| Q3 24 | 30.0% | 0.9% | ||
| Q2 24 | 29.9% | -4.3% | ||
| Q1 24 | 21.7% | -3.1% |
| Q4 25 | $0.20 | $0.62 | ||
| Q3 25 | $0.15 | $0.42 | ||
| Q2 25 | $0.14 | $0.12 | ||
| Q1 25 | $0.11 | $-0.10 | ||
| Q4 24 | $0.45 | $0.17 | ||
| Q3 24 | $0.15 | $0.03 | ||
| Q2 24 | $0.13 | $-0.11 | ||
| Q1 24 | $0.08 | $-0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $403.4M |
| Total DebtLower is stronger | $72.1M | — |
| Stockholders' EquityBook value | $477.3M | $962.3M |
| Total Assets | $624.2M | $1.3B |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $403.4M | ||
| Q3 25 | $61.4M | $376.9M | ||
| Q2 25 | $90.3M | $371.1M | ||
| Q1 25 | $71.6M | $420.8M | ||
| Q4 24 | $103.1M | $384.3M | ||
| Q3 24 | $86.7M | $348.4M | ||
| Q2 24 | $88.2M | $342.7M | ||
| Q1 24 | $45.3M | $368.9M |
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $477.3M | $962.3M | ||
| Q3 25 | $431.2M | $943.8M | ||
| Q2 25 | $398.3M | $947.8M | ||
| Q1 25 | $373.4M | $948.9M | ||
| Q4 24 | $349.0M | $957.7M | ||
| Q3 24 | $231.9M | $932.1M | ||
| Q2 24 | $188.3M | $951.9M | ||
| Q1 24 | $153.7M | $949.1M |
| Q4 25 | $624.2M | $1.3B | ||
| Q3 25 | $568.7M | $1.2B | ||
| Q2 25 | $558.4M | $1.2B | ||
| Q1 25 | $510.6M | $1.3B | ||
| Q4 24 | $488.7M | $1.3B | ||
| Q3 24 | $390.6M | $1.2B | ||
| Q2 24 | $376.4M | $1.2B | ||
| Q1 24 | $350.9M | $1.2B |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | — |
| Free Cash FlowOCF − Capex | $34.6M | — |
| FCF MarginFCF / Revenue | 24.8% | — |
| Capex IntensityCapex / Revenue | 0.8% | 0.1% |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | — | ||
| Q3 25 | $13.3M | $57.4M | ||
| Q2 25 | $21.1M | $-15.8M | ||
| Q1 25 | $-19.7M | — | ||
| Q4 24 | $50.2M | $45.1M | ||
| Q3 24 | $25.0M | $55.6M | ||
| Q2 24 | $45.6M | $-9.3M | ||
| Q1 24 | $-2.2M | — |
| Q4 25 | $34.6M | — | ||
| Q3 25 | $-1.1M | $56.8M | ||
| Q2 25 | $18.7M | $-16.2M | ||
| Q1 25 | $-24.4M | — | ||
| Q4 24 | $47.5M | $44.8M | ||
| Q3 24 | $24.0M | $55.4M | ||
| Q2 24 | $43.6M | $-9.6M | ||
| Q1 24 | $-4.6M | — |
| Q4 25 | 24.8% | — | ||
| Q3 25 | -0.8% | 28.4% | ||
| Q2 25 | 15.3% | -8.3% | ||
| Q1 25 | -21.2% | — | ||
| Q4 24 | 40.4% | 22.9% | ||
| Q3 24 | 20.0% | 29.8% | ||
| Q2 24 | 40.7% | -5.4% | ||
| Q1 24 | -5.6% | — |
| Q4 25 | 0.8% | 0.1% | ||
| Q3 25 | 10.7% | 0.3% | ||
| Q2 25 | 2.0% | 0.2% | ||
| Q1 25 | 4.1% | 0.2% | ||
| Q4 24 | 2.3% | 0.1% | ||
| Q3 24 | 0.9% | 0.1% | ||
| Q2 24 | 1.9% | 0.1% | ||
| Q1 24 | 2.9% | 1.0% |
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | 2.09× | ||
| Q2 25 | 0.62× | -2.04× | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | 4.02× | ||
| Q3 24 | 0.70× | 32.10× | ||
| Q2 24 | 1.42× | — | ||
| Q1 24 | -0.12× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
RAMP
Segment breakdown not available.
